Mckean, M., Chmielowski, B., Butler, M. O., Carvajal, R., Rodon, J., Carlino, M., … Orloff, M. (2023). 1081O ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM). In Annals of Oncology (Vol. 34, pp. S651–S651). Elsevier BV. https://doi.org/10.1016/j.annonc.2023.09.2215

Mckean, M., B. Chmielowski, M. O. Butler, R. Carvajal, J. Rodon, M. Carlino, K. B. Kim, et al. “1081O ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM).” In Annals of Oncology, 34:S651–S651. Elsevier BV, 2023. https://doi.org/10.1016/j.annonc.2023.09.2215.

Mckean M, Chmielowski B, Butler MO, Carvajal R, Rodon J, Carlino M, et al. 1081O ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM). In: Annals of Oncology. Elsevier BV; 2023. p. S651–S651.

Mckean, M., et al. “1081O ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM).” Annals of Oncology, vol. 34, Elsevier BV, 2023, pp. S651–S651. Crossref, doi:10.1016/j.annonc.2023.09.2215.

Mckean M, Chmielowski B, Butler MO, Carvajal R, Rodon J, Carlino M, Kim KB, Wise-draper T, Khan S, Salama AKS, Moser J, Reeves J, Wilner KD, Maurer M, Abed M, Mitchell B, Beaupre D, Orloff M. 1081O ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM). Annals of Oncology. Elsevier BV; 2023. p. S651–S651.